What's new? Log in Free sign up

Evoke Pharma (EVOK)

Company Profile

evoke pharma is a biotechnology company located in 505 lomas santa fe dr, solana beach, california, united states.

Company profile

Ticker

EVOK

Exchange

Website

evokepharma.com/

CEO

David Gonyer

Incorporated

Location

Fiscal year end

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Bausch Health Companies • Celgene ...

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Material Contracts & Credit Agreements

IRS number

208447886

EVOK stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

Registration of securities for employees

Evoke Pharma Reports Second Quarter 2023 Financial Results

Quarterly report

10 Aug 23

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

Confidential treatment order

Evoke Pharma Reports First Quarter 2023 Financial Results

Quarterly report

15 May 23

Departure of Directors or Certain Officers

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

KENNETH J WIDDER

Matthew J D'Onofrio

MARILYN R. CARLSON

KENNETH J WIDDER

Financial summary

Financial statements Chart EVOK financial data

Quarter (USD)	Jun 23	Mar 23	Dec 22	Sep 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	7.01 mm	7.01 mm	7.01 mm	7.01 mm	7.01 mm	7.01 mm
Cash burn (monthly)	402.12 k	537.04 k	594.81 k	630.16 k	402.12 k	537.04 k
Cash used (since last report)	1.22 mm	1.63 mm	1.81 mm	1.92 mm	1.22 mm	1.63 mm
Cash remaining	5.78 mm	5.37 mm	5.20 mm	5.09 mm	5.78 mm	5.37 mm
Runway (months of cash)	14.4	10.0	8.7	8.1	14.4	10.0

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q2 2023

EVOK institutional ownership history Ownership history

52.7% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	10	12	-16.7%
Opened positions	1	2	-50.0%
Closed positions	3	2	+50.0%
Increased positions	1	2	-50.0%
Reduced positions	1	1	–

13F shares	Current	Prev Q	Change
Total value	100.14 mm	104.90 mm	-4.5%
Total shares	1.76 mm	1.77 mm	-0.6%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Hirschman Orin	1.70 mm	$2.76 mm	0.0%
Vanguard	29.85 k	$49.25 mm	0.0%
Geode Capital Management	20.89 k	$34.27 mm	0.0%
Tower Research Capital	5.58 k	$9.21 mm	+40.0%
BLK Blackrock	1.47 k	$2.43 mm	0.0%
UBS UBS Group AG - Registered Shares	1.11 k	$1.83 mm	0.0%
GWM Advisors	208.00	$343.00 k	0.0%
Concord Wealth Partners	31.00	$51.00 k	-72.8%
RY Royal Bank Of Canada	28.00	$0.00	0.0%
CWM	16.00	$0.00	NEW

Largest transactions	Shares	Bought/sold	Change
Renaissance Technologies	0.00	-11.18 k	EXIT
Tower Research Capital	5.58 k	+1.60 k	+40.0%
Concord Wealth Partners	31.00	-83.00	-72.8%
Lindbrook Capital	0.00	-83.00	EXIT
CWM	16.00	+16.00	NEW
WFC Wells Fargo & Co.	0.00	-16.00	EXIT
Vanguard	29.85 k	0.00	0.0%
Proequities	0.00	0.00
RY Royal Bank Of Canada	28.00	0.00	0.0%
Hirschman Orin	1.70 mm	0.00	0.0%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

EVOK insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
10 May 23	Todd C Brady	Stock Option Common Stock	Grant	Acquire A	No	No	2.12	14,625	31.01 k	14,625
10 May 23	Garner Cam L	Stock Option Common Stock	Grant	Acquire A	No	No	2.12	17,750	37.63 k	17,750
10 May 23	Hill Malcolm R	Stock Option Common Stock	Grant	Acquire A	No	No	2.12	14,625	31.01 k	14,625
10 May 23	Vickie S Reed	Stock Option Common Stock	Grant	Acquire A	No	No	2.12	15,000	31.80 k	15,000
10 May 23	Widder Kenneth J	Stock Option Common Stock	Grant	Acquire A	No	No	2.12	14,250	30.21 k	14,250

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

12 Health Care Stocks Moving In Friday's Intraday Session

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Stocks That Hit 52-Week Lows On Tuesday

On Tuesday, 210 companies reached new 52-week lows.

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Stocks That Hit 52-Week Lows On Monday

Press releases

From Benzinga Pro

Evoke Pharma Receives Notice of Allowance from USPTO for GIMOTI®

SOLANA BEACH, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on

Evoke Pharma Reports Second Quarter 2023 Financial Results

40% revenue growth compared to Q1 2023 34% increase in prescription fills compared to Q1 2023 Presented industry-leading real-world healthcare utilization data supporting the benefits of GIMOTI compared to oral

Evoke Pharma and EVERSANA Announce Abstract Acceptance at 2023 American Neurogastroenterology and Motility Society (ANMS) Meeting

Real-world study that explored the healthcare utilization resource utilization among patients receiving GIMOTI with and without prior treatment with oral metoclopramide Both organizations recognize and support

Evoke Pharma and EVERSANA Announce Abstract Selection for Plenary Oral Presentation at The American College of Gastroenterology (ACG) 2023 Annual Meeting

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.